Tonix Pharmaceuticals (OTCBB: TNXP) develops new treatments for challenging disorders of the central nervous system (CNS). The Company’s lead programs are potential new treatments for fibromyalgia and post-traumatic stress disorder, which are chronic CNS syndromes. In each of these programs, TONIX seeks to use new doses and formulations of cyclobenzaprine in new treatment regimens. Cyclobenzaprine is the active ingredient of two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration (FDA) and are marketed by other companies.
The company has announced that Chief Executive Officer Seth Lederman, M.D. will be presenting at the inaugural Marcum MicroCap Conference on June 20th at the Roosevelt Hotel in New York City. Dr. Lederman's presentation is scheduled to begin at 3:30 p.m. Eastern time.
A live audio webcast of this presentation will be available through the conference website: http://execvid.com/marcum-microcap-conference-2012
The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization and will feature presentations by CEOs and CFOs of approximately 60 promising high-growth companies, as well as panel discussions. This invitation-only event is expected to attract top fund managers who focus on small cap equities and qualified high-net-worth investors.
For full event details and registration information, please visit http://www.marcumllp.com/microcap.